{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:30:15Z","timestamp":1781789415879,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.euo.2024.02.010","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T13:34:39Z","timestamp":1710336879000},"page":"313-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-886X","authenticated-orcid":false,"given":"David J.","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Rezazadeh Kalebasty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.euo.2024.02.010_b0005","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV + P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.02.010_b0010","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.02.010_b0015","unstructured":"Kresge N, Cattan N. Merck, Seagen drug combo seen as new bladder cancer standard. Bloomberg, October 22, 2023. https:\/\/www.bnnbloomberg.ca\/merck-seagen-drug-cocktail-seen-as-new-bladder-cancer-standard-1.1988001"},{"key":"10.1016\/j.euo.2024.02.010_b0020","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2024.02.010_b0025","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1200\/JCO.2023.41.6_suppl.508","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy","volume":"41","author":"Sridhar","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.02.010_b0030","unstructured":"AstraZeneca. Antibody drug conjugates (ADCs). AstraZeneca, July 2020. https:\/\/www.astrazeneca.com\/our-therapy-areas\/oncology\/antibody-drug-conjugates.html"},{"key":"10.1016\/j.euo.2024.02.010_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2023.100451","article-title":"Starting and stopping cancer drugs: the need for randomized controlled trials","volume":"38","author":"Benjamin","year":"2023","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.euo.2024.02.010_b0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-023-00765-8","article-title":"Patient preferences in the treatment of genitourinary cancers","volume":"20","author":"Benjamin","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2024.02.010_b0045","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.1007\/s00520-022-07234-9","article-title":"Shared burden: the association between cancer diagnosis, financial toxicity, and healthcare cost-related coping mechanisms by family members of non-elderly patients in the USA","volume":"30","author":"Kazzi","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.euo.2024.02.010_b0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T01:25:41Z","timestamp":1715822741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2588931124000580"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.02.010","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}